Alexion Pharmaceuticals (Alexion Pharmaceuticals) Change In Inventory : $-2 Mil (TTM As of Mar. 2021)

View and export this data going back to 1996. Start your Free Trial

What is Alexion Pharmaceuticals Change In Inventory?

Alexion Pharmaceuticals's change in inventory for the quarter that ended in Mar. 2021 was $-60 Mil. It means Alexion Pharmaceuticals's inventory increased by $60 Mil from Dec. 2020 to Mar. 2021 .

Alexion Pharmaceuticals's change in inventory for the fiscal year that ended in Dec. 2020 was $95 Mil. It means Alexion Pharmaceuticals's inventory declined by $95 Mil from Dec. 2019 to Dec. 2020 .

Alexion Pharmaceuticals's Total Inventories for the quarter that ended in Mar. 2021 was $804 Mil.

Days Inventory indicates the number of days of goods in sales that a company has in the inventory. Alexion Pharmaceuticals's Days Inventory for the quarter that ended in Mar. 2021 was 574.71.

Inventory Turnover measures how fast the company turns over its inventory within a year. Alexion Pharmaceuticals's Inventory Turnover for the quarter that ended in Mar. 2021 was 0.16.

Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue. Alexion Pharmaceuticals's Inventory-to-Revenue for the quarter that ended in Mar. 2021 was 0.48.

Alexion Pharmaceuticals Change In Inventory Historical Data

The historical data trend for Alexion Pharmaceuticals's Change In Inventory can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Alexion Pharmaceuticals Change In Inventory Chart

Alexion Pharmaceuticals Annual Data

Trend

Dec11

Dec12

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Change In Inventory

Get a 7-Day Free Trial

-83.80

-88.20

-35.20

-160.20

95.00

Alexion Pharmaceuticals Quarterly Data
	Jun16	Sep16	Dec16	Mar17	Jun17	Sep17	Dec17	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21
Change In Inventory	Get a 7-Day Free Trial															37.30	-52.40	4.80	105.30	-59.50

Alexion Pharmaceuticals Change In Inventory Calculation

Change In Inventory is the difference between last period's ending inventory and the current period's ending inventory.

Change In Inventory for the trailing twelve months (TTM) ended in Mar. 2021 adds up the quarterly data reported by the company within the most recent 12 months, which was $-2 Mil.

Alexion Pharmaceuticals (NAS:ALXN) Change In Inventory Explanation

1. Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

Alexion Pharmaceuticals's Days Inventory for the quarter that ended in is calculated as:

Days Inventory	=	Average Total Inventories	/	Cost of Goods Sold	*	Days in Period
	=	789.8	/	125.4	*	365 / 4
	=	574.71

2. Inventory Turnover measures how fast the company turns over its inventory within a year.

Alexion Pharmaceuticals's Inventory Turnover for the quarter that ended in Mar. 2021 is calculated as

Inventory Turnover	=	Cost of Goods Sold	/	Average Total Inventories
	=	125.4	/	789.8
	=	0.16

3. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.

Alexion Pharmaceuticals's Inventory to Revenue for the quarter that ended in Mar. 2021 is calculated as

Inventory-to-Revenue	=	Average Total Inventories	/	Revenue
	=	789.8	/	1636.5
	=	0.48

Alexion Pharmaceuticals Change In Inventory Related Terms

Thank you for viewing the detailed overview of Alexion Pharmaceuticals's Change In Inventory provided by GuruFocus.com. Please click on the following links to see related term pages.

Alexion Pharmaceuticals (Alexion Pharmaceuticals) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Alexion Pharmaceuticals Inc (NAS:ALXN) » Definitions » Change In Inventory

Comparable Companies

Traded in Other Exchanges

N/A

Address

121 Seaport Boulevard, Boston, MA, USA, 02210

Website

https://www.alexion.com

Alexion Pharmaceuticals specializes in developing and marketing drugs for rare, life-threatening medical conditions. Its blockbuster product, Soliris, is approved for paroxysmal nocturnal hemoglobinuria (PNH), atypical hemolytic uremic syndrome (aHUS), generalized myasthenia gravis (gMG), and neuromyelitis optica spectrum disorder (NMOSD). Next-generation Ultomiris is approved in PNH and aHUS. Strensiq and Kanuma target ultrarare metabolic diseases. Alexion's pipeline targets rare diseases with high unmet need in hematology, nephrology, metabolic diseases, neurology, cardiology, and other areas.

Executives

Daniel Bazarko	officer: SVP, Controller, CAO	C/O ALEXION PHARMACEUTICALS, INC. 121 SEAPORT BOULEVARD BOSTON MA 02210
Tanisha Carino	officer: EVP & CCAO	C/O ALEXION PHARMACEUTICALS, INC., 121 SEAPORT BOULEVARD, BOSTON MA 02210
Anne-marie Law	officer: EVP, Chief Experience Officer	C/O BAXALTA INCORPORATED, 1200 LAKESIDE DRIVE, BANNOCKBURN IL 60015
Brian Goff	officer: EVP & Chief Commercial Officer	C/O ALEXION PHARMACEUTICALS, INC, 100 COLLEGE STREET, NEW HAVEN CT 06510
John J Orloff	officer: EVP, Research & Development	C/O BAXALTA INCORPORATED 1200 LAKESIDE DRIVE BANNOCKBURN IL 60015
Indrani Lall Franchini	officer: EVP, Chief Compliance Officer	C/O ALEXION PHARMACEUTICALS, INC, 100 COLLEGE STREET, NEW HAVEN CT 06510
John T Mollen	director	176 SOUTH STREET HOPKINTON MA 01748
David R Brennan	director	C/O INSMED INCORPORATED, 10 FINDERNE AVENUE, BRIDGEWATER NJ 08807
Baker Bros. Advisors (gp) Llc	director	860 WASHINGTON STREET, 3RD FLOOR, NEW YORK NY 10014
L.p. 667,	director	860 WASHINGTON STREET, 3RD FLOOR, NEW YORK NY 10014
Andreas Rummelt	director	C/O ALEXION PHARMACEUTICALS, INC. 352 KNOTTER DRIVE CHESHIRE CT 06410
Francois Nader	director	550 HILLS DRIVE, BEDMINSTER NJ 07921
Baker Brothers Life Sciences Lp	director	860 WASHINGTON STREET, 3RD FLOOR, NEW YORK NY 10014
Deborah Dunsire	director	C/O ULTRAGENYX PHARMACEUTICAL INC., 60 LEVERONI COURT, NOVATO CA 94949
Judith A Reinsdorf	director	C. R. BARD, INC., 730 CENTRAL AVENUE, MURRAY HILL NJ 07974